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25 Abstract. Long non-coding RNAs (lncRNAs) are RNA transcripts over 200 nucleotides long 
26 that are not translated into protein; however, there is increasing evidence of their regulatory 
27 functions. To date, there are few studies measuring lncRNA in control women or women with 
28 polycystic ovary syndrome (PCOS). 
29 Objective. To determine lncRNA differences between PCOS and control women.
30 Methods LncRNA were measured in 24 anovulatory women with all three diagnostic features 
31 of PCOS compared to 24 control women in the follicular phase of their menstrual cycle from 
32 a PCOS biobank.
33 Results. Women with PCOS were age and weight matched compared to the control women 
34 but were significantly insulin resistant and hyperandrogenemic (p<0.01). Eight lncRNA (p 
35 <0.05) were detected that differed between PCOS and control women, but only MIRLET7BHG 
36 correlated with body mass index (r=0.66, p<0.05). No lncRNA correlated with anti-mullerian 
37 hormone (AMH) levels, insulin resistance (HOMA-IR) or the free androgen index (FAI).  
38 Ingenuity pathway assessment (IPA) did not identify any functional pathways for the lncRNAs.
39 Conclusion. LncRNAs differ between anovulatory PCOS and control women in the follicular 
40 phase of the menstrual cycle.  It is unclear if this is due to inherent differences between PCOS 
41 and control women or due to changes in lncRNA that are menstrual cycle dependent. However, 





































































48 Polycystic ovarian syndrome (PCOS) affects 9-21% of the female population, making it one 
49 of the most common endocrine disorders amongst women of reproductive age, and it is the 
50 major cause of anovulatory infertility (1). The clinical and biochemical hyperandrogenism 
51 characteristic of PCOS are associated with insulin resistance (IR), obesity, type 2 diabetes, 
52 and hypercholesterolemia (2). Though the etiology of PCOS is poorly understood, genetic 
53 abnormalities, such as mutations, epigenetic alterations and changes in noncoding RNAs, are 
54 considered to be major underlying etiological factors (3-5).
55 The ENCODE project established that, in both humans and rodents, only approximately 2% 
56 of the genome is transcribed into coding sequences, the vast majority being transcribed into 
57 noncoding sequences. These noncoding sequences include microRNAs, small interfering 
58 RNAs and long noncoding RNAs (lncRNAs) (6, 7). Long noncoding RNAs are transcripts 
59 greater than 200 nucleotides in length that lack protein-coding capacity. An understanding of 
60 their mechanistic role in diverse biological processes is accumulating (8). Evidence indicates 
61 that they have regulatory role in development, differentiation, proliferation and apoptosis and 
62 their involvement in diseases such as diabetes (9), cardiovascular disease (10), neurological 
63 disorders (11), and cancer (8). More recently, differential expression of 862 lncRNA 
64 transcripts (692 upregulated, 170 downregulated) was reported in granulosa cells from 
65 Chinese women with PCOS undergoing in vitro fertilization (IVF) therapy (12); however, the 
66 number of women in the study (7 PCOS, 7 controls) was limited. 
67 Given the limited data on lncRNA in PCOS, our study was designed to use serum samples 
68 from the PCOS Biobank collected within the follicular phase in normal women to compare 
69 circulating levels of lncRNAs in Caucasian women with PCOS versus controls. The lncRNA 
70 were not preselected but rather those that were detected from each of the RNA libraries 
71 constructed.
































































73 Materials and methods
74
75 Study design: This was a cross sectional study undertaken in 24 medication naïve women with 
76 PCOS and biochemical hyperandrogenaemia (age 18-45 years) who presented sequentially to 
77 the department of endocrinology and those who fulfilled the criteria of the study were recruited 
78 into the local PCOS biobank at United Kingdom (ISRCTN70196169). Twenty-four control 
79 women (age 20-44 years) who were age and body mass index (BMI) matched to the PCOS 
80 women were included into this study. Subject demographics are shown in Table 1. The 
81 diagnosis of PCOS was based on fulfilling all three diagnostic criteria of the Rotterdam 
82 consensus, namely clinical and biochemical evidence of hyperandrogenemia (Ferriman-
83 Gallwey score >8; free androgen index  >4 respectively), oligomenorrhea or amenorrhea and 
84 polycystic ovaries on transvaginal ultrasound (classical phenotype) (13).  Liver ultrasound was 
85 performed at the same time to exclude non-alcoholic fatty liver disease. Study participants had 
86 no concurrent illness, and were not on any medication for the preceding nine months. None of 
87 the women had successful pregnancy or miscarriage at least five year prior to study entry. 
88 Diabetes was excluded by a 75g oral glucose tolerance test. Non-classical 21-hydroxylase 
89 deficiency, hyperprolactinaemia, Cushing’s disease and androgen-secreting tumours were 
90 excluded by appropriate tests.  All women gave written informed consent.  This study was 
91 approved by the Newcastle & North Tyneside Ethics committee, UK.  
92 Sample collection: Blood samples were taken after an overnight fast during the follicular 
93 phase of the menstrual cycle in control women and serum was stored frozen at -80OC pending 
94 analysis. All PCOS women were anovulatory (3 months amenorrhea; random progesterone less 
95 than 5nmol/l). Serum testosterone and androstenedione were measured by isotope dilution 
96 liquid chromatography-tandem mass spectrometry (Waters Corporation, Manchester, UK). Sex 
97 hormone binding globulin (SHBG) was determined by an immunometric assay with 
98 fluorescence detection on the DPC Immulite 2000 analyzer using the manufacturer’s 































































99 recommended protocol. The free androgen index was obtained as the total testosterone 
100 x100/SHBG. Serum insulin was assayed using a competitive chemiluminescent immunoassay 
101 performed on the manufacturer’s DPC Immulite 2000 analyzer (Euro/DPC, Llanberis, UK). 
102 The analytical sensitivity of the insulin assay was 2 µU/ml, the coefficient of variation was 6%, 
103 and there was no stated cross-reactivity with proinsulin. Plasma glucose was measured using a 
104 Synchron LX20 analyzer (Beckman-Coulter), using the manufacturer’s recommended 
105 protocol. The coefficient of variation for the assay was 1.2% at a mean glucose value of 5.3 
106 mmol/liter during the study period. The insulin resistance was calculated using the HOMA 
107 method [HOMA-IR=(insulin x glucose)/22.5], and pancreatic beta cell sensitivity measured by 
108 HOMA—β [HOMA-β=(20 x insulin)/glucose -3.5].   
109 RNA preparation and analysis Following RNA extraction: Approximately 20ng of total 
110 RNA was used to generate strand-specific paired end 75bp Illumina libraries with NEXTFLEX 
111 Rapid Directional RNA-Seq Library Prep Kit (Bio-Scientific, Austin, TX) according to the 
112 manufacturer’s protocol. Briefly, the protocol included the following steps: first strand cDNA 
113 synthesis, second strand synthesis, A- tailing, adaptor ligation and purification, followed by 
114 UDG treatment, library amplification and purification.  Library quality and quantity were 
115 analyzed with the Bioanalyzer 2100 (Agilent, Santa Clara, CA) on a High Sensitivity DNA 
116 chip. Six libraries were then pooled in equimolar ratios and sequenced on one lane of an 
117 Illumina HiSeq 4000 run (Illumina, San Diego, CA). Average sequencing depth for the libraries 
118 is 16 million reads.
119 RNA-seq data analysis: We performed quality check for the read with FastQC (14). Reads 
120 with adaptors and rRNA contamination were removed using BBMap (15). After filtering, the 
121 reads were mapped to human reference genome from Ensembl GRCh38 release 93 (16) with 
122 STAR (17) using Ensembl 93 gene annotation(16). For mapped read quantification, we used 
123 featureCounts function from Rsubread package (18) in R (19). 































































124 Following quantification, lncRNA were identified and the lncRNAs were then quantified using 
125 Wald test from DESeq2 (20). P value <0.05 was taken as the cutoff for significance.
126 Statistical analysis: There was no information for lncRNA on which to base a sample size 
127 calculation.  For such pilot studies, Birkett and Day (14) suggest a minimum of 20 degrees of 
128 freedom to estimate variance from which a larger trial could be powered. We recruited 24 for 
129 each group to allow for drop-outs and covariate adjustment. Statistical analysis was performed 
130 using SPSS (v22, Chicago, Illinios). Descriptive data is presented as mean ± SD for continuous 
131 data and n (%) for categorical data. T-tests or Mann Whitney tests were used to compare 
132 means/medians where appropriate. Linear associations were assessed using the Pearson’s 
133 correlation test. 
134 Results: 
135 Baseline characteristics of the 24 PCOS and 24 control women are shown in Table 1. The 
136 PCOS and control women did not differ for age or BMI; however, the PCOS women showed 
137 greater insulin resistance and hyperandrogenemia (p<0.01), androstenedione did not differ.
138 There were 8 significant lncRNAs between the PCOS and control women (Table 2).  Of 
139 those, MIRLET7BHG significantly correlated with BMI (r 0.66, p<0.05). No lncRNA 
140 correlated with age, AMH, HOMA-IR, testosterone, androstenedione or the FAI. All of the 
141 lncRNA detected are shown in Supplementary Table 1. 
142 When Ingenuity pathway analysis was undertaken to look at the functional relationships, no 
143 pathway could be constructed when taking the top 10, top 25, top 50 or top 70 lncRNAs into 
144 account.
145 Discussion
146 Next generation sequencing (NGS) has provided a wealth of novel information about 
147 genomic organization and regulation of gene expression, with non-coding (non-translated) 
148 RNAs being identified as important regulators of gene expression (15). Whilst thousands of 































































149 lncRNAs have now been identified, functional characterization has only been determined in a 
150 small subset but has indicated that they are involved in numerous physiological processes, 
151 working at the epigenetic, transcriptional and post-transcriptional level (16). Information to 
152 date has shown that their dysregulation is associated with a wide variety of diseases including 
153 cancer (8), neurological disorders(11), cardiovascular disease(10) and diabetes (9). At least 
154 19 lncRNAs are associated with diabetes in humans (17), some directly affecting pancreatic 
155 beta-cells, with others acting as a link between insulin signaling and insulin resistance (18). 
156 Insulin resistance is an integral component of PCOS, and the prevalence of T2DM is 
157 increased in women with PCOS (2), therefore aberrant expression of lncRNAs in serum of 
158 women with PCOS might be anticipated, and indeed the findings are not unexpected.     
159 This study suggests that there are significant alterations of lncRNAs in subjects with PCOS 
160 compared to age and BMI matched control subjects in the normal women in the follicular 
161 phase of the menstrual cycle compared to the anovulatory PCOS. 
162 In women with PCOS compared to controls, there were 8 lncRNAs that differed significantly. 
163 Using www.genecard.org, MALAT1 (metastasis associated lung adenocarcinoma transcript 
164 1) is thought to provide molecular scaffolds for ribonuclear proteins and is associated with 
165 cancer progression. MIR181A1HG is associated with acute myeloid leukaemia. The 
166 functions of the other lncRNAs (AC005332.6, AC009404.1, PSMG3-AS1, MIRLET7BHG, 
167 AC016831.6 and AC012313.1) are unknown. 
168 Reported phenotypes associated with the lncRNA include BMI (AP001999.1 and IQCH-
169 AS1), systolic blood pressure (AC093459.1 and AC016831.6), type 2 diabetes (AC016831.6) 
170 dyslipidemia (AC016831.6) and PCOS (LINC01828) ( www.genecard.org). Given that little 
171 function has to date been ascribed to lncRNAs, it may therefore be understood why no 
172 functional pathways could be constructed with the Ingenuity Pathway assessment tool.































































173 Correlation was undertaken for the significant lncRNAs for the follicular phase with age, 
174 BMI, AMH, HOMA-IR and FAI, but only MIRLET7BHG correlated with BMI in the 
175 follicular phase. However, the sample size was too small to exclude a type 2 statistical error.
176 This pilot study was limited by the small number of subjects but the strength of the study was 
177 that all of the PCOS women fulfilled all 3 of the diagnostic Rotterdam criteria providing 
178 homogeneity. A comparison with PCOS subjects without the metabolic phenotype would 
179 have been of value. The study clearly showed that lncRNAs may be found in PCOS and that 
180 they differ from control women. However, given that the lncRNA did not correlate to either 
181 insulin resistance or androgen levels then it may suggest that the differences could be more 
182 related to the menstrual cycle, but there is no data on lncRNA throughout the menstrual cycle 
183 to answer this.
184 In conclusion, lncRNA were found to differ between PCOS and control women in the 
185 follicular phase of the menstrual cycle, though functional pathway analysis was limited by 
186 the unknown functions of many of the lncRNAs. The phase of the menstrual cycle may be 
187 important for lncRNA expression and that needs to be taken into account in future studies. 
188
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Table 1. Demographics, biochemical and clinical markers (mean±SD) for the PCOS and 






 Mean SD Mean S D
P-value
Age (years) 32.4 7.8 31.6 8.8 0.735
BMI 27.2 6.0 28.8 5.6 0.324
Glucose (mmo/l) 4.6 0.5 4.8 0.6 0.202
Insulin mIU/ml) 7.3 4.9 12.0 6.1 0.012
HOMA IR 1.5 0.9 2.6 1.7 0.006
Androstenedione 
(nmol/l) 8.3 4.8 10.6 6.6 0.21
Testosterone (nmol/l) 1.0 0.4 2.5 1.6 0.007
SHBG (mmol/l) 76.4 76.1 46.6 51.0 0.167
FAI 2.0 1.0 12.4 18.0 0.013
(BMI, body mass index; FAI, free androgen index; SHBG, sex hormone binding globulin; 
HOMA-IR, homeostatic model assessment-insulin resistance)






























































Table 2. Significant long non coding RNA (n=8) in patients unselected for date of menstrual 
cycle for patients with PCOS and control women. 







































































Supplementary Table 1. All long non coding RNA (significant n=8) in patients unselected for 
date of menstrual cycle for patients with PCOS and control women. 
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